Here are five things to know:
1. The CyPass Micro-Stent was approved by the FDA in 2016 to use with cataract surgery in adults with glaucoma.
2. A long-term safety study revealed that five years post-surgery, patients with implanted CyPass Micro-Stents experienced statistically significant endothelial cell loss compared to the group who underwent cataract surgery alone.
3. The voluntary recall applies to all versions of the CyPass Micro-Stent.
4. “We believe that withdrawing the CyPass Micro-Stent from the market is in patients’ best interest and is the right thing to do,” said Stephen Lane, MD, CMO of Alcon.
5. Alcon is contacting surgeons with recommendations for evaluating and managing the patients who have already received the stent.
More articles on supply chain:
Data accuracy, clinical integration & more: 3 takeaways from AHRMM’s Supply Chain Conference
Kaiser changes EpiPen prescription policy after complaints
A drug to treat hemophilia, Non-Hodgkin lymphoma & more: 4 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
